<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_gWCqQ35">Digital Health Interventions to Enhance Tuberculosis Treatment Adherence: Scoping Review</title>
				<funder ref="#_erkTH9h">
					<orgName type="full">Severance Hospital</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Sol</forename><surname>Lee</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Yonsei University Health System , Yonsei University , Seoul , Republic of Korea</note>
								<orgName type="institution" key="instit1">Yonsei University Health System</orgName>
								<orgName type="institution" key="instit2">Yonsei University</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Vasuki</forename><surname>Rajaguru</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Healthcare Management , Graduate School of Public Health , Yonsei University , Seoul , Republic of Korea</note>
								<orgName type="department" key="dep1">Department of Healthcare Management</orgName>
								<orgName type="department" key="dep2">Graduate School of Public Health</orgName>
								<orgName type="institution">Yonsei University</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Joon</forename><forename type="middle">Sang</forename><surname>Baek</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Human Environment &amp; Design , Yonsei University , Seoul , Republic of Korea</note>
								<orgName type="department">Department of Human Environment &amp; Design</orgName>
								<orgName type="institution">Yonsei University</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Jaeyong</forename><surname>Shin</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Preventive Medicine , College of Medicine , Yonsei University , Seoul , Republic of Korea</note>
								<orgName type="department" key="dep1">Department of Preventive Medicine</orgName>
								<orgName type="department" key="dep2">College of Medicine</orgName>
								<orgName type="institution">Yonsei University</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> Institute for Innovation in Digital Healthcare , Yonsei University , Seoul , Republic of Korea</note>
								<orgName type="department">Institute for Innovation in Digital Healthcare</orgName>
								<orgName type="institution">Yonsei University</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">;</forename><forename type="middle">Youngmok</forename><surname>Park</surname></persName>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> Institute for Innovation in Digital Healthcare , Yonsei University , Seoul , Republic of Korea</note>
								<orgName type="department">Institute for Innovation in Digital Healthcare</orgName>
								<orgName type="institution">Yonsei University</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> Division of Pulmonary and Critical Care Medicine , Department of Internal Medicine , Severance Hospital , Yonsei University College of Medicine , Seoul , Republic of Korea</note>
								<orgName type="department" key="dep1">Division of Pulmonary and Critical Care Medicine</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Severance Hospital</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Youngmok</forename><surname>Park</surname></persName>
						</author>
						<author>
							<affiliation key="aff6">
								<note type="raw_affiliation">Division of Pulmonary and Critical Care Medicine , Department of Internal Medicine Severance Hospital , Yonsei University College of Medicine 50-1 Yonsei-ro , Seodaemun-gu Seoul , 03722 Republic of Korea</note>
								<orgName type="department" key="dep1">Division of Pulmonary and Critical Care Medicine</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine Severance Hospital</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
								<address>
									<addrLine>50-1 Yonsei-ro Seodaemun-gu</addrLine>
									<postCode>03722</postCode>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_db3PnPV">Digital Health Interventions to Enhance Tuberculosis Treatment Adherence: Scoping Review</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">3BE60134C960D848693D7C88393FBE73</idno>
					<idno type="DOI">10.2196/49741</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T12:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_PQDez3C">tuberculosis</term>
					<term xml:id="_8ud9chh">patient compliance</term>
					<term xml:id="_hnZWJ4t">digital health</term>
					<term xml:id="_d3GgUra">medication adherence</term>
					<term xml:id="_u4RNbXV">text messaging</term>
					<term xml:id="_NnVfZHj">mobile apps</term>
					<term xml:id="_NGNB9zj">application</term>
					<term xml:id="_fbMxRKe">medication</term>
					<term xml:id="_d3gbpFq">text</term>
					<term xml:id="_nJD23SY">scoping review</term>
					<term xml:id="_US76Mbd">disease management</term>
					<term xml:id="_Y2bXMZA">chronic disease</term>
					<term xml:id="_nNUwAAR">communication</term>
					<term xml:id="_qN3835y">feedback</term>
					<term xml:id="_bcaxQ5Z">self-management</term>
					<term xml:id="_XgXv22p">PRISMA</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_6kNSHNG"><p xml:id="_v4bKzqE"><s xml:id="_d4MfYsT">Background: Digital health technologies are widely used for disease management, with their computing platforms, software, and sensors being used for health care.</s><s xml:id="_8BHPRPc">These technologies are developed to manage chronic diseases and infectious bacterial diseases, including tuberculosis (TB).</s></p><p xml:id="_EHGDZKG"><s xml:id="_jbgyZT2">Objective: This study aims to comprehensively review the literature on the use of digital health interventions (DHIs) for enhancing TB treatment adherence and identify major strategies for their adoption.</s><s xml:id="_EWMXyxr">Methods: We conducted a literature search in the PubMed, Cochrane Library, Ovid Embase, and Scopus databases for relevant studies published between January 2012 and March 2022.</s><s xml:id="_DksJ8kG">Studies that focused on web-based or mobile phone-based interventions, medication adherence, digital health, randomized controlled trials, digital interventions, or mobile health and ubiquitous health technology for TB treatment and related health outcomes were included.</s><s xml:id="_v8eSXzz">Results: We identified 27 relevant studies and classified them according to the intervention method, a significant difference in treatment success, and health outcomes.</s><s xml:id="_rV63CZQ">The following interventions were emphasized: SMS text messaging interventions (8/27, 30%), medicine reminders (6/27, 22%), and web-based direct observation therapy (9/27, 33%).</s><s xml:id="_E7gwUWH">Digital health technology significantly promoted disease management among individuals and health care professionals.</s><s xml:id="_2pfYkHz">However, only a few studies addressed 2-way communication therapies, such as interactive SMS text messaging and feedback systems.</s><s xml:id="_ytGKPqS">Conclusions: This scoping review classified studies on DHIs for patients with TB and demonstrated their potential for the self-management of TB.</s><s xml:id="_HhZQ3kN">DHIs are still being developed, and evidence on the impact of digital technologies on enhancing TB treatment adherence remains limited.</s><s xml:id="_q33fJSV">However, it is necessary to encourage patients' participation in TB treatment and self-management through bidirectional communication.</s><s xml:id="_7KMnVx9">We emphasize the importance of developing a communication system.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Ep8fGKT">Introduction</head><p xml:id="_pk4NRhP"><s xml:id="_eFewzVd">Until the COVID-19 pandemic, tuberculosis (TB) was the leading cause of death from a single infectious disease, affecting approximately 10.6 million people in 2021 <ref type="bibr" target="#b0">[1]</ref>.</s><s xml:id="_xXxac5V">TB can be cured with appropriate medications; however, treatment adherence is affected by the complexity, tolerability, and long duration of the available regimens.</s><s xml:id="_kKZcZYE">Since low adherence increases the risk of poor treatment outcomes, several interventions have been attempted to enhance TB medication adherence <ref type="bibr" target="#b1">[2]</ref>.</s></p><p xml:id="_cuvE8dH"><s xml:id="_FpU7Rfh">Digital health interventions (DHIs) are promising for patient-centered care, as they allow for the remote monitoring of patients and can be used to conveniently remind patients to take their medications.</s><s xml:id="_6afswtc">Numerous studies have addressed how to enhance medication adherence during treatment by using mobile technologies, such as SMS text messaging <ref type="bibr" target="#b2">[3]</ref>, directly observed therapy (DOT) <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>, video calls, phone call reminders <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>, and web-based reports <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref>.</s><s xml:id="_pNeeuRb">Studies have reported satisfaction <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref>, accuracy <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref>, acceptable uptake <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8]</ref>, improved drug adherence <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b8">9]</ref>, higher rates of treatment success <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8]</ref>, and user acceptance <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref> with regard to DHIs in TB management.</s><s xml:id="_cDJqskQ">This review aims to summarize the existing literature on DHIs for TB treatment adherence, classify DHI techniques, identify the different types of interventions and their effects on treatment effectiveness, and evaluate adherence and health outcomes in TB treatment.</s><s xml:id="_nCTN5JV">This study reports on treatment outcomes, self-care management, follow-up, and the value of mobile-based communication activities that aim to improve TB treatment adherence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sxjZ4ty">Methods</head><p xml:id="_ShnJC8T"><s xml:id="_EFcwKBP">We followed Arksey and O'Malley's <ref type="bibr" target="#b10">[11]</ref> 5-stage scoping review framework, the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement <ref type="bibr" target="#b11">[12]</ref>, and the Joanna Briggs Institute protocol <ref type="bibr" target="#b12">[13]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ARbZuUp">Identifying the Relevant Studies</head><p xml:id="_a8zBsh9"><s xml:id="_gnHTtuW">We conducted a literature search in the PubMed, Cochrane Library, Ovid Embase, and Scopus databases for relevant studies published between January 2012 and March 2022.</s><s xml:id="_3za3EXd">A comprehensive search strategy was developed to identify relevant studies, which included but was not confined to the following search string: ("Tuberculosis" OR "TB" OR "Tuberculosis infection") AND ("RCT" OR "Randomized controlled trial" OR "Experimental study") AND ("Behavior therapy" OR "Cognitive behavioral treatment" OR "Digital intervention" OR "Digital therapeutics" OR "Appbased" OR "Web-based" OR "mHealth" OR "uHealth") AND ("treatment adherence" OR "medication adherence" OR "selfcare" OR "Management" OR "Persistence" OR "Compliance").</s><s xml:id="_JbEJqfq">The search terms and strategies are presented in Multimedia Appendix 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KfT4Wu8">Eligibility and Exclusion Criteria</head><p xml:id="_kdGBmQb"><s xml:id="_uMKnXNY">We included articles that met the following criteria: <ref type="bibr" target="#b0">(1)</ref> published in peer-reviewed journals, (2) included TB treatment adherence and health outcomes as part of the study design, (3) written in English, (4) had full text available, and (5) published between January 2012 and March 2022.</s><s xml:id="_ZQpxkbA">Studies were excluded if they were published before 2011 or did not focus on DHIs for TB.</s><s xml:id="_fPCrvNU">Reviews, case studies, reports, letters, conference proceedings, and abstract-only articles were also excluded.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_GcXpKBp">Study Selection and Data Synthesis</head><p xml:id="_RzwtmQ2"><s xml:id="_cbUYBwY">Duplicates were eliminated from each database and recorded in the first stage.</s><s xml:id="_bnrSySX">The second stage involved reviewing study titles and abstracts to ensure that articles were research studies that focused on digital health technology as a main intervention tool to improve the treatment adherence of patients with TB.</s><s xml:id="_XPzZgdk">The full texts of the articles were scrutinized in the last stage to verify whether they satisfied the key requirements.</s></p><p xml:id="_dpTp2EG"><s xml:id="_GQuAHQd">Data were extracted by 1 reviewer (SL), and 2 independent reviewers (VR and YP) charted the data on different characteristics, including authors, publication year, country, study design, target population, number of participants, type of DHI, duration, follow-up, outcome measures, and major findings.</s></p><p xml:id="_RBnXMWg"><s xml:id="_FNKVmpM">The retrieved data suggested that the core attributes of digital intervention strategies fell under the following three domains, which were based on the DHIs found in the selected articles: sending reminders via SMS text messages, monitoring progress, and tracking follow-ups for the self-management of TB treatment outcomes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_P7rfb6E">Quality Assessment and Risk of Bias</head><p xml:id="_uETB9XE"><s xml:id="_v4CT9Us">Two independent reviewers (SL and YP) evaluated the risk of bias as part of the quality assessment, using the Cochrane Collaboration's tool for assessing the risk of bias (RoB 2 [Risk of <ref type="bibr">Bias 2]</ref>; version: August 9, 2019) <ref type="bibr" target="#b13">[14]</ref>.</s><s xml:id="_CHEMeNH">The risk of bias was assessed based on 5 domains, and bias scores were assigned ("low risk," "some concern," or "high risk").</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dEnHSPh">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_VNbUKTN">Search Results</head><p xml:id="_QbpZmpG"><s xml:id="_5D8Syt9">The literature search retrieved 305 articles; 72 duplicates were excluded, and 172 did not meet the inclusion criteria, based on the title and abstract review.</s><s xml:id="_T8MrgD4">As a result, 61 articles were screened for the full-text review, and 34 were excluded owing to implications regarding the exclusion criteria and unavailability of full texts.</s><s xml:id="_WMjMWZu">Ultimately, 27 studies were finalized for the data synthesis (Figure <ref type="figure" target="#fig_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vJzuDF9">Characteristics of the Selected Articles</head><p xml:id="_9z5NWFu"><s xml:id="_hjka4Kt">Given the novelty of digital health technology in TB treatment, the number of publications was observed to have increased since 2018.</s><s xml:id="_3m4Djt7">A total of 27 articles  were selected; their characteristics are described in Multimedia Appendix 2. Most of the studies (19/27, 70%) were published in or after 2019 <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref>.</s></p><p xml:id="_DngcyPu"><s xml:id="_qmJxpac">With regard to the study designs, 17 studies were randomized controlled trials (RCTs) <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b37">38]</ref>, 8 were RCT protocols <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40]</ref>, and 2 were quasi-experimental studies <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b40">41]</ref>.</s><s xml:id="_E8tepTT">Further, 13 studies were published in lowand middle-income countries (LMICs), including countries in Africa <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b39">40]</ref> and Asia <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b40">41]</ref>.</s><s xml:id="_qt2xqSx">Digital health technology for TB is actively used in LMICs due to the high prevalence of TB (Multimedia Appendix 3).</s><s xml:id="_neCQPXt">The combined study population was aged &gt;18 years and included participants who were diagnosed with TB or were taking TB medication.</s><s xml:id="_B5hmwwA">The average number of participants was 400.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UxrvZmT">Types of DHIs</head><p xml:id="_rtP6gV7"><s xml:id="_CAUFEbX">Table <ref type="table" target="#tab_0">1</ref> and Figure <ref type="figure" target="#fig_1">2</ref> present the most common technologies used in DHIs, including the duration, frequency, and outcomes of interventions.</s><s xml:id="_WfWHABT">The commonest DHIs were SMS text messages and reminder messages (8/27, 30%) <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref>, DOT (9/27, 33%) <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref>, medication event reminder monitors (MERMs; 6/27, 22%) <ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref>, and mobile apps (4/27, 15%) <ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref>.</s><s xml:id="_vsQw7wG">DOT-based DHIs included video observation therapy (VOT) <ref type="bibr" target="#b24">[25]</ref>, electronic DOT (e-DOT) <ref type="bibr" target="#b30">[31]</ref>, and wearable bracelet self-DOT <ref type="bibr" target="#b22">[23]</ref>.</s><s xml:id="_gdGhRjh">Some studies evaluated a mix of interventions, including mobile app-based video observations <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b38">39]</ref>, a web intervention <ref type="bibr" target="#b23">[24]</ref>, WhatsApp (Meta Platforms Inc) <ref type="bibr" target="#b37">[38]</ref>, and WeChat (Tencent Holdings Ltd) <ref type="bibr" target="#b38">[39]</ref>.</s><s xml:id="_EtNXCC5">MERMs <ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref> were also used to determine the feasibility of a web-based follow-up <ref type="bibr" target="#b35">[36]</ref> and a mobile-based (ie, evriMED1000 [Wisepill Technologies]) follow-up with phone call <ref type="bibr" target="#b33">[34]</ref> reminders to enhance treatment adherence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_GZvmbGN">Components of the DHIs and Outcomes</head><p xml:id="_VyDrqPP"><s xml:id="_83VGJ9S">Table <ref type="table" target="#tab_1">2</ref> presents the components of DHIs that were derived from the primary and secondary outcomes of the selected articles, including (1) sending reminders for treatment adherence via reinforcement SMS text messages <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref>, (2) monitoring treatment adherence by using digital technology <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref>, and (3) tracking treatment adherence through the use of mobile apps and mobile health (mHealth) technology <ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref> via treatment adherence <ref type="bibr" target="#b41">[42]</ref> and modified behavior adherence <ref type="bibr" target="#b42">[43]</ref> models.</s><s xml:id="_GQBfjCK">Figure <ref type="figure" target="#fig_2">3</ref> presents a modified adherence model.</s><s xml:id="_p2Jfccv">Adherence to tuberculosis treatment is a repeated and ongoing self-management behavior.</s><s xml:id="_YvnwbNP">In this figure, reminding refers to reminding patients to take medications as prescribed (ie, correct dose, frequency, and time), monitoring refers to using digital health technology (eg, an app) to check whether patients are taking their medication at the prescribed frequency over the initial period, and tracking refers to following patients over time to determine whether they taking medications as prescribed <ref type="bibr" target="#b42">[43]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_n3rQ2sQ">Quality Assessment of the Selected Articles</head><p xml:id="_MNr88eh"><s xml:id="_edYxY8W">A risk of bias assessment was performed to assess the quality of the selected articles.</s><s xml:id="_jSXPbm7">Only 8 of the 27 articles used an RCT design <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b36">37]</ref>. The risk of bias results are shown in Multimedia Appendix 4 <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b36">37]</ref> and Multimedia Appendix 5.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bFefU85">Discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_pcQFM7A">Principal Results</head><p xml:id="_xB5Kvqx"><s xml:id="_Z4SaRXG">This review aimed to identify DHIs related to TB treatment and management.</s><s xml:id="_ZcPdUue">We retrieved the relevant articles from electronic databases by using standard search terms and identified 27 articles published between 2012 and 2022.</s><s xml:id="_CT5u4uH">DHIs for improving treatment adherence were categorized as DHIs for sending reminders <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref>, DHIs for monitoring <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref>, and DHIs for tracking <ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref>.</s><s xml:id="_gKzeYED">We identified various types of DHIs, including SMS text messaging <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref>, DOT <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref>, MERMs <ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref>, and mobile apps <ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref>, which improved the effectiveness of self-management, treatment adherence, and the prevention of TB in clinical and community settings.</s></p><p xml:id="_CFgj6p2"><s xml:id="_D5wcsS6">A total of 19 studies focused on different types of interventions for reminding patients about treatment adherence and included outcomes such as medication adherence <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b40">41]</ref>, self-reported survey satisfaction <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b21">22]</ref>, and appointment attendance <ref type="bibr" target="#b19">[20]</ref>.</s><s xml:id="_7HbT9Zr">Treatment adherence was primarily accomplished through daily reminder SMS text messages <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref> and phone calls <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b40">41]</ref> that requested confirmation of adherence.</s><s xml:id="_ejQ5v73">Furthermore, additional reminders were sent to patients for encouragement or motivation <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b19">20]</ref> if they did not respond within a given time period <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b27">28]</ref>.</s><s xml:id="_mAuqtX4">Studies also reported sending compliance reminders through daily quizzes <ref type="bibr" target="#b17">[18]</ref>; sending reinforcement SMS text messages twice weekly for 12 weeks <ref type="bibr" target="#b20">[21]</ref>; and sending system reminders or additional messages to remind patients about the time of medication use <ref type="bibr" target="#b16">[17]</ref>, confirm daily doses <ref type="bibr" target="#b27">[28]</ref>, notify patients about a consultation service for their upcoming monthly visits <ref type="bibr" target="#b31">[32]</ref>, encourage the use of an app <ref type="bibr" target="#b20">[21]</ref>, and promote self-satisfaction <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b26">27]</ref>.</s><s xml:id="_5ev9xaA">Rather than demonstrate treatment efficacy, SMS text messaging-based reminder interventions increased patient satisfaction <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b18">19]</ref>.</s><s xml:id="_k3MEzW9">SMS text messaging-based digital technology supports and helps patients and health care professionals to enhance health practices and clinical outcomes.</s><s xml:id="_GfvpkAN">An interactive reminder, such as an SMS text message or video conversation, should be developed according to the required medical monitoring process and incorporated into clinical practice.</s></p><p xml:id="_KvR3CFF"><s xml:id="_sWwV6DS">Numerous studies have examined the use of DOT to monitor treatment adherence, including 99DOTS <ref type="bibr" target="#b27">[28]</ref>, VOT <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b38">39]</ref>, asynchronous VOT <ref type="bibr" target="#b29">[30]</ref>, wireless observation therapy <ref type="bibr" target="#b23">[24]</ref>, and e-DOT <ref type="bibr" target="#b39">[40]</ref>.</s><s xml:id="_yjynGyM">DOT also includes treatment regimen monitoring interventions that are based on technology, such as wearable devices <ref type="bibr" target="#b22">[23]</ref>, mHealth apps <ref type="bibr" target="#b28">[29]</ref>, and wireless devices <ref type="bibr" target="#b23">[24]</ref>.</s><s xml:id="_FnbqXb5">We identified 8 articles that reported e-DOT interventions for TB treatment adherence.</s><s xml:id="_ER7UKxn">Prior studies reported that participants preferred e-DOT over traditional therapy for supporting daily TB medication use during the long-term phase of TB treatment <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30</ref>].</s><s xml:id="_3VJhqS3">e-DOT should be tested in areas with a high risk of TB contraction, as e-DOT could greatly enhance the development of programs for treating the disease in LMICs.</s><s xml:id="_rXYAb2r">In addition, VOT interventions for new TB cases were used in combination with a mobile app <ref type="bibr" target="#b25">[26]</ref>, WeChat (for education and knowledge) <ref type="bibr" target="#b38">[39]</ref>, and treatment follow-up (with a maximum follow-up interval of 6 months).</s><s xml:id="_a9QBKjh">Story et al <ref type="bibr" target="#b25">[26]</ref> reported that VOT resulted in an 80% medication adherence rate in 2 months when compared to DOT, and Ravenscroft et al <ref type="bibr" target="#b28">[29]</ref> reported that VOT resulted in about a 45% decrease in nonadherence, which was statistically significant.</s><s xml:id="_mpz5Kau">Further, smartphone-enabled video surveillance of TB therapy has been proven successful and has many advantages over conventional DOT.</s><s xml:id="_mAPfK5n">Wade et al <ref type="bibr" target="#b43">[44]</ref> found that VOT increased the proportion of observed treatment doses when compared to DOT; however, the effect on the treatment adherence rate was not statistically significant.</s><s xml:id="_yGW2DyE">Thus, audioand video-based DHIs may be useful in reducing attrition and improving treatment adherence and health outcomes in acute care settings.</s></p><p xml:id="_ZVFh4yR"><s xml:id="_cYGw5w4">In this review, 4 RCT protocols for MERM-related monitoring interventions were also included <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36]</ref> to obtain data on the methodological pattern of treatment adherence.</s><s xml:id="_bvUCyN9">Most MERMs are designed to ensure drug compliance, such as evriMED500 <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33]</ref> or evriMED1000 <ref type="bibr" target="#b34">[35,</ref><ref type="bibr" target="#b35">36]</ref>.</s><s xml:id="_NmGnS3w">Maraba et al <ref type="bibr" target="#b34">[35]</ref> developed an MERM for the daily monitoring of patients and children with drug-susceptible TB during a 6-to 12-month follow-up.</s><s xml:id="_X3KPBrm">Additionally, et al <ref type="bibr" target="#b33">[34]</ref> conducted a clinical trial of an MERM for patients with pulmonary TB for approximately 6 months; a total of 54 doses were delivered over 70 days, and the adherence rate was approximately 90%.</s><s xml:id="_p7VwZMW">Further, Acosta et al <ref type="bibr" target="#b36">[37]</ref> reported that an MERM was significantly more effective than DOT.</s><s xml:id="_cEfKy6Q">Hence, we suggest that further RCTs using MERM-based digital intervention strategies should be conducted to enhance TB treatment adherence and clinical outcomes.</s><s xml:id="_ers5DfV">Since most outcomes were self-reported, additional trials are recommended to determine the accuracy of MERM system-based adherence rates.</s></p><p xml:id="_88ncnJb"><s xml:id="_n9RhZM4">Tracking and guiding patients remain important for the follow-up of treatment adherence in a therapeutic context.</s><s xml:id="_XSgMRej">We found that 4 smartphone-, mHealth-, and mobile app-based digital devices were used to evaluate TB treatment adherence <ref type="bibr" target="#b33">[34,</ref><ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b40">41]</ref> and acceptability <ref type="bibr" target="#b37">[38]</ref>.</s><s xml:id="_dnr6e3m">Patients with pulmonary TB who received intervention through the WhatsApp TB@Clicks module (an mHealth-based DHI) were approximately 4.1 times more likely to have favorable treatment results than a control group <ref type="bibr" target="#b37">[38]</ref>.</s><s xml:id="_u4St9ST">Another DHI for daily drug tracking resulted in drug adherence rates increasing from 85.5% to 96.4% over time <ref type="bibr" target="#b40">[41]</ref>, and a health-related VOT resulted in decreased nonadherence rates within 4 days <ref type="bibr" target="#b28">[29]</ref>.</s><s xml:id="_S8VE3P5">Some apps were combined with a mobile-based pillbox system for a second consultation, resulting in satisfaction and confidence among patients <ref type="bibr" target="#b33">[34]</ref>.</s><s xml:id="_yD7suht">These outcomes must be incorporated into future clinical trial designs that adopt trustworthy quantitative methods to determine the relative contribution of each digital health technology component.</s><s xml:id="_c59SPs8">This review's findings revealed that DHIs encouraged self-management among patients with TB and empowered them to participate in collaborative discussions during consultations.</s><s xml:id="_wCjUe97">However, we found that studies on real-time, conversation-based digital technology are lacking; such technology could improve treatment adherence and foster positive health outcomes in various clinical settings.</s><s xml:id="_VfQ6sMj">Due to the rapid development of artificial intelligence technologies, including digital tool kits and generative artificial intelligence, 2-way communication-based chatbots in TB treatment may lead to improved self-management in patients with TB.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vzz8Ahe">Limitations</head><p xml:id="_8kU9qze"><s xml:id="_7mGUJ8r">This review had some limitations.</s><s xml:id="_dx85msj">First, our review included studies that focused on treatment outcome-based interventions rather than health care delivery.</s><s xml:id="_k2xAwR2">Therefore, we did not focus on other details, such as TB prevalence, costs, or health insurance.</s><s xml:id="_6yGzhaN">Second, this study focused on the effects of commonly used DHIs on TB treatment outcomes in clinical and community settings.</s><s xml:id="_UrFd5Fe">Further studies should determine how DHIs vary between the two contexts and how they interact with multidomain therapies.</s><s xml:id="_KUdZSXN">Third, this study did not specifically describe treatment adherence and self-management.</s><s xml:id="_eHf8JFD">There are no clear differences between the accurate meaning and measurement of treatment adherence in a clinical trial setting and those of self-management in a clinical or community context, and few studies have attempted to provide answers <ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref>.</s><s xml:id="_9JwN5Z3">Fourth, many of the included studies (13/27, 48%) were conducted in LMICs because of the high prevalence of TB cases, even though high-income nations have a considerable number of studies.</s><s xml:id="_gXsRfsj">This could be attributed to our study's selection criteria, such as our criterion for language.</s><s xml:id="_A3Eg8py">Therefore, additional studies are required to identify DHIs across the entire TB care continuum.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ZdMwHVb">Conclusions</head><p xml:id="_hAv9Ycz"><s xml:id="_GZx8v4S">This study examined 27 studies published between 2012 and 2022 and selected the most recent articles.</s><s xml:id="_8cvDqx9">The following three domains were identified from the selected studies: reminding, monitoring, and tracking.</s><s xml:id="_5dYRpbQ">The preponderance of treatment adherence was reinforced by mHealth strategies, such as the use of SMS text messaging, mobile apps, mHealth technology, and MERMs.</s><s xml:id="_XjS6nET">Our findings have implications for TB-related digital health research, which frequently fails to adequately address patients with TB.</s><s xml:id="_TFusTDn">To preserve treatment adherence and self-care management, patients should have access to real-time, conversation-based interventions (dialogue or communication between patients and health care professionals), such as mobile-or app-based chats, regardless of the restrictions imposed by the COVID-19 pandemic.</s><s xml:id="_ctKvARV">This scoping review study was conducted before our ongoing chatbot project, which focuses on a mixed methods study on chatbot communication for the treatment adherence of patients with TB.</s><s xml:id="_YsazsNB">Thus, we emphasize the importance of developing a communication system.</s><s xml:id="_gvQuS8b">DHIs provide several advantages, including improved patient engagement, availability, and accessibility, in addition to lower workloads for practitioners.</s><s xml:id="_9apFS7U">These results should be considered in the context of national TB control programs and policies to establish a strategy for sustaining TB control and health outcomes.</s><s xml:id="_pVS7vuf">We propose that these developments can significantly improve TB treatment adherence through global collaboration and investment.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p xml:id="_aYdDZTU"><s xml:id="_gVXgZEX">Figure 1.</s><s xml:id="_xynJm78">PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram for selection of articles.</s><s xml:id="_WGnwnYA">RCT: randomized controlled trial.</s></p></div></figDesc><graphic coords="3,93.63,95.40,409.00,410.86" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p xml:id="_HnTsP8K"><s xml:id="_GEPGXfD">Figure 2. Types of digital health interventions and the number of articles published by year.</s><s xml:id="_PxJgZJX">e-DOT: electronic directly observed therapy; MERM: medication event reminder monitor; mHealth: mobile health.</s></p></div></figDesc><graphic coords="6,93.63,95.40,409.00,228.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p xml:id="_faFz4Mv"><s xml:id="_2g8jJEK">Figure 3.Adherence to tuberculosis treatment is a repeated and ongoing self-management behavior.</s><s xml:id="_g3P8Uuy">In this figure, reminding refers to reminding patients to take medications as prescribed (ie, correct dose, frequency, and time), monitoring refers to using digital health technology (eg, an app) to check whether patients are taking their medication at the prescribed frequency over the initial period, and tracking refers to following patients over time to determine whether they taking medications as prescribed<ref type="bibr" target="#b42">[43]</ref>.</s></p></div></figDesc><graphic coords="7,93.63,115.80,409.00,212.43" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_bpHEtsu"><s xml:id="_EuCQMqb">Description of digital health technology tuberculosis (TB) interventions and related outcomes.</s></p></div></figDesc><table><row><cell>Study Intervention Main outcome Bedian g et al SMS text Treatment success messaging [15] van der Kop et SMS text Treatment success messaging al [16] Moham med et SMS text Treatment success messaging al [17] Herman s et al SMS text messaging Risk of LFU a in the first 2 mo of treatment [18] Farooqi et al SMS text Treatment default messaging [19] Bedian g et al SMS text messaging Treatment success [20] Moriart y et al SMS text messaging TB treatment results according to the WHO c [21] Sahile et al SMS text Treatment adherence messaging [22] Huang et al e-DOT g TB treatment results according to the WHO c [23] Browne e-DOT Positive detection accuracy et al [24] Holzma e-DOT Treatment adherence n et al [25] Story et e-DOT Treatment adherence al [26] Khacha dourian e-DOT Treatment success et al [27] Crowde e-DOT Treatment adherence r et al [28] Ravens e-DOT Treatment adherence croft et al [29] Doltu et al [30] e-DOT Treatment adherence Burzyn ski et al [31] e-DOT Completed doses and percentage differences between electronic vs in-person DOT j Lewis et al MERM l TB treatment results according to the WHO c [32] Manyaz ewal et al [33] MERM Treatment adherence and sputum conversion</cell><cell>Secondary outcomes Treatment adherence, multidrug resistance, and satisfaction 6 mo Duration Treatment adherence and treatment completion 9 mo Treatment adherence and physical health measures 6 mo Treatment success, completion, adherence, satisfaction, and 2 mo knowledge TB treatment results according to the WHO c,d 2 mo Self-reported adherence regarding attending appointments 6 mo and satisfaction Smoking cessation, reduction in alcohol use, and treatment 6 mo adherence ACTG e , VAS f , and clinic appointment attendance 2 mo Treatment adherence, MGLS h , knowledge, and quality of 6 mo life Treatment adherence Other i Proportion of all prescribed treatment Other i Treatment outcomes and health-related quality of life 6 mo Treatment adherence, depressive symptoms, quality of life, 4-5 mo and social support as nonclinical outcomes Reduced risk of LFU and cost-effectiveness 14 mo Treatment success at 12 mo 4 mo Living conditions, health insurance before TB, previous 3 mo treatment history, and mode of intensive phase Proportion of medication doses, patient adherence, and Other k quality of care Adherence outcomes and cost-effectiveness outcomes 6 mo Adverse treatment outcomes, cost-effectiveness, and usability 15 d</cell><cell>Frequency Daily Weekly Daily Other b Daily Daily Twice weekly Daily Daily Daily Daily Daily Daily Daily Daily Daily Daily Daily Daily</cell></row></table><note xml:id="_DSYF6Mq"><p><s xml:id="_vy7Jpf9">a LFU: loss to follow-up.</s><s xml:id="_cm7ZTWk">b Compliance notifications (2, 7, and 11 d after the most recent appointment), appointment notifications (every 2 wk), and educational quizzes (3, 6, 9, and 12 d after the most recent appointment).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p xml:id="_AhwEBxn"><s xml:id="_7yFm4BA">Distribution of digital health interventions (DHIs) and related interventions (N=27).</s></p></div></figDesc><table><row><cell>Components and DHIs</cell></row></table><note xml:id="_yUmZBuH"><p><s xml:id="_YCqNUet">a DOT: directly observed therapy.</s><s xml:id="_NjsvFqa">b e-DOT: electronic directly observed therapy.</s><s xml:id="_NN4rQMb">c VOT: video observation therapy.</s><s xml:id="_zFKegnU">d WOT: wireless observation therapy.</s><s xml:id="_fC9qRKF">e MERM: medication event reminder monitor.</s><s xml:id="_37CDyvp">f mHealth: mobile health.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_zcVtkKM"><s xml:id="_pZGXkhP">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_wFVmfpU">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_uzP24Fb">11 | e49741 | p. 2 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_Me8dfTT"><s xml:id="_WqZrzvc">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_wwUPkh8">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_f2kabWF">11 | e49741 | p. 3 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2"><p xml:id="_vGvyPPn"><s xml:id="_Ah2HGsN">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_5hHZK8F">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_Ykf9SYm">11 | e49741 | p. 4 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_3"><p xml:id="_B3Zy3hb"><s xml:id="_V8smskU">c Cured, treatment completed, treatment failed, died, lost to follow-up, not evaluated, or treatment success.</s><s xml:id="_Mnw3PX6">d WHO: World Health Organization.</s><s xml:id="_NGWYAsZ">e ACTG: AIDS Clinical Trial Group adherence questionnaire.</s><s xml:id="_t2C4zAC">f VAS: visual analog scale.</s><s xml:id="_Gj42k9C">g e-DOT: electronic directly observed therapy.</s><s xml:id="_uxZfXJa">h MGLS: Morisky, Green, and Levine Adherence Scale.</s><s xml:id="_NvRctaX">i Until TB treatment completion.</s><s xml:id="_vkTRe3V">j DOT: directly observed therapy.</s><s xml:id="_AVShDC5">k Completed 20 medication doses using 1 DOT method, then switched methods for another 20 doses.</s><s xml:id="_nYfHkRa">l MERM: medication event reminder monitor.</s><s xml:id="_xwqh5pv">m mHealth: mobile health.</s><s xml:id="_r7MEDSK">n Smartphone mobile app.</s><s xml:id="_ZpJ4jD4">o N/A: not applicable.</s><s xml:id="_B7SR5cx">p DOT for a minimum period of 30 d and a maximum of 90 d.</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_4"><p xml:id="_gRQtb9V"><s xml:id="_JgjvgTF">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_ptg4tAG">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_WXfEWbk">11 | e49741 | p. 5 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_5"><p xml:id="_XYjX9gR"><s xml:id="_pBAFtJc">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_AtEqbKW">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_yvHCjXw">11 | e49741 | p. 6 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_6"><p xml:id="_Xw92CYZ"><s xml:id="_uXnhHx8">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_jsxcYCz">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_NWuCVfd">11 | e49741 | p. 7 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_7"><p xml:id="_XGGPYkR"><s xml:id="_k345AmZ">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_pd3hyUh">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_6FyGnQ6">11 | e49741 | p. 8 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_8"><p xml:id="_kRCkktN"><s xml:id="_pwsh3uV">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_kjA9FqD">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_jQq2SeR">11 | e49741 | p. 9 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_9"><p xml:id="_wsj9yj4"><s xml:id="_Ecw6MXq">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_AcYkCfQ">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_gz3YqD6">11 | e49741 | p. 10 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_10"><p xml:id="_wmx8GvX"><s xml:id="_tB6wDh4">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_4kTZjMU">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_bNTBNTP">11 | e49741 | p. 11 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_11"><p xml:id="_GMvzzbh"><s xml:id="_Gh5VN4G">https://mhealth.jmir.org/2023/1/e49741</s><s xml:id="_HGkREBS">JMIR mHealth and uHealth 2023 | vol.</s><s xml:id="_VFQxaBu">11 | e49741 | p. 12 (page number not for citation purposes)</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_3yTzyxv">Acknowledgments</head><p xml:id="_SdCxwGz"><s xml:id="_a6M5Fcw">This study was supported by the <rs type="funder">Severance Hospital</rs> <rs type="grantName">Research Fund for Clinical Excellence Grant</rs> (grant number: <rs type="grantNumber">C-2022-0017</rs>).</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_erkTH9h">
					<idno type="grant-number">C-2022-0017</idno>
					<orgName type="grant-name">Research Fund for Clinical Excellence Grant</orgName>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UKUyNHB">Authors' Contributions</head><p xml:id="_XSHzVcJ"><s xml:id="_mhybh3H">YP, JSB, and JS conceived and designed this study and were responsible for the methodology.</s><s xml:id="_htVHPvJ">SL and VR conducted the data extraction.</s><s xml:id="_ye83ZSV">SL, VR, and YP conducted the formal analysis.</s><s xml:id="_DFZ45e9">SL and VR wrote the manuscript.</s><s xml:id="_NKWPdzG">All authors contributed to manuscript revision.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EexJycg">Conflicts of Interest</head><p xml:id="_8S57SKj"><s xml:id="_FXYTDDh">None declared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bzFjr6R">Multimedia</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main" xml:id="_PbKGNj6">Global tuberculosis report</title>
		<idno type="DOI">10.1001/jamahealthforum.2022.4994</idno>
		<ptr target="https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022" />
		<imprint>
			<date type="published" when="2022">2022. 2022. 2023-11-10</date>
			<publisher>World Health Organization</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Global tuberculosis report 2022. World Health Organization. 2022. URL: https://www.who.int/teams/global- tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 [Accessed 2023-11-10]</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_GXaM3hH">Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies</title>
		<author>
			<persName><forename type="first">N</forename><surname>Alipanah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jarlsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Miller</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.1002595</idno>
		<idno>Medline: 29969463</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_f9qmTGW">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">1002595</biblScope>
			<date type="published" when="2018-07-03">2018 Jul 3</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Alipanah N, Jarlsberg L, Miller C, et al. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018 Jul 3;15(7):e1002595. [doi: 10.1371/ journal.pmed.1002595] [Medline: 29969463]</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_DcrNVQY">The impact of digital health technologies on tuberculosis treatment: a systematic review</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Ngwatu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Nsengiyumva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Oxlade</surname></persName>
		</author>
		<idno type="DOI">10.1183/13993003.01596-2017</idno>
		<idno>Medline: 29326332</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FgnFK6C">Eur Respir J</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">1701596</biblScope>
			<date type="published" when="2018-01-11">2018 Jan 11</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J. 2018 Jan 11;51(1):1701596. [doi: 10.1183/13993003.01596-2017] [Medline: 29326332]</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_KrvAQGU">Monitoring therapy compliance of tuberculosis patients by using video-enabled electronic devices</title>
		<author>
			<persName><forename type="first">A</forename><surname>Story</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Garfein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hayward</surname></persName>
		</author>
		<idno type="DOI">10.3201/eid2203.151620</idno>
		<idno>Medline: 26891363</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MnxU8YH">Emerg Infect Dis</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="538" to="540" />
			<date type="published" when="2016-03">2016 Mar</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Story A, Garfein RS, Hayward A, et al. Monitoring therapy compliance of tuberculosis patients by using video-enabled electronic devices. Emerg Infect Dis. 2016 Mar;22(3):538-540. [doi: 10.3201/eid2203.151620] [Medline: 26891363]</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_TWwtDM9">Digital health technologies to improve medication adherence and treatment outcomes in patients with tuberculosis: systematic review of randomized controlled trials</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ridho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Alfian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jfm</forename><surname>Van Boven</surname></persName>
		</author>
		<idno type="DOI">10.2196/33062</idno>
		<idno>Medline: 35195534</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nZvjSJq">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">33062</biblScope>
			<date type="published" when="2022-02-23">2022 Feb 23</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ridho A, Alfian SD, van Boven JFM, et al. Digital health technologies to improve medication adherence and treatment outcomes in patients with tuberculosis: systematic review of randomized controlled trials. J Med Internet Res. 2022 Feb 23;24(2):e33062. [doi: 10.2196/33062] [Medline: 35195534]</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_Q2WHaeG">Use of digital technology to enhance tuberculosis control: scoping review</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Raviglione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Flahault</surname></persName>
		</author>
		<idno type="DOI">10.2196/15727</idno>
		<idno>Medline: 32053111</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rQP7KFt">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">15727</biblScope>
			<date type="published" when="2020-02-13">2020 Feb 13</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lee Y, Raviglione MC, Flahault A. Use of digital technology to enhance tuberculosis control: scoping review. J Med Internet Res. 2020 Feb 13;22(2):e15727. [doi: 10.2196/15727] [Medline: 32053111]</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_8fDRJQr">Enhancing management of tuberculosis treatment with video directly observed therapy in New York City</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Macaraig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Burzynski</surname></persName>
		</author>
		<idno type="DOI">10.5588/ijtld.15.0738</idno>
		<idno>Medline: 27084810</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Pa4dKqG">Int J Tuberc Lung Dis</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="588" to="593" />
			<date type="published" when="2016-05">2016 May</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. Int J Tuberc Lung Dis. 2016 May;20(5):588-593. [doi: 10.5588/ijtld. 15.0738] [Medline: 27084810]</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_MNmkbKx">Evaluation of the accuracy of 99DOTS, a novel cellphone-based strategy for monitoring adherence to tuberculosis medications: comparison of digital adherence data with urine isoniazid testing</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chiranjeevi</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciaa333</idno>
		<idno>Medline: 32221550</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ds28Fb4">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="513" to="e516" />
			<date type="published" when="2020-12-03">2020 Dec 3</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thomas BE, Kumar JV, Chiranjeevi M, et al. Evaluation of the accuracy of 99DOTS, a novel cellphone-based strategy for monitoring adherence to tuberculosis medications: comparison of digital adherence data with urine isoniazid testing. Clin Infect Dis. 2020 Dec 3;71(9):e513-e516. [doi: 10.1093/cid/ciaa333] [Medline: 32221550]</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_HtNpFdW">Electronic medication monitor for people with tuberculosis: implementation experience from thirty counties in China</title>
		<author>
			<persName><forename type="first">N</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Shewade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Thekkur</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0232337</idno>
		<idno>Medline: 32348351</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VQHvKac">PLoS One</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">232337</biblScope>
			<date type="published" when="2020-04-29">2020 Apr 29</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang N, Shewade HD, Thekkur P, et al. Electronic medication monitor for people with tuberculosis: implementation experience from thirty counties in China. PLoS One. 2020 Apr 29;15(4):e0232337. [doi: 10.1371/journal.pone.0232337] [Medline: 32348351]</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_S3EjBrH">Assessment of directly observed therapy (DOT) following tuberculosis regimen change in Addis Ababa, Ethiopia: a qualitative study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Fiseha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Demissie</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12879-015-1142-2</idno>
		<idno>Medline: 26423277</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_e6BXMn4">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">405</biblScope>
			<date type="published" when="2015-09-30">2015 Sep 30</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fiseha D, Demissie M. Assessment of directly observed therapy (DOT) following tuberculosis regimen change in Addis Ababa, Ethiopia: a qualitative study. BMC Infect Dis. 2015 Sep 30;15:405. [doi: 10.1186/s12879-015-1142-2] [Medline: 26423277]</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_RZd4F2W">From Arksey and O&apos;Malley and beyond: customizations to enhance a team-based, mixed approach to scoping review methodology</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Westphaln</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Regoeczi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Masotya</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.mex.2021.101375</idno>
		<idno>Medline: 34430271</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_b2MDY4T">MethodsX</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">101375</biblScope>
			<date type="published" when="2021-05-07">2021 May 7</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Westphaln KK, Regoeczi W, Masotya M, et al. From Arksey and O&apos;Malley and beyond: customizations to enhance a team-based, mixed approach to scoping review methodology. MethodsX. 2021 May 7;8:101375. [doi: 10.1016/j.mex. 2021.101375] [Medline: 34430271]</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_RJDpNWv">The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration</title>
		<author>
			<persName><forename type="first">A</forename><surname>Liberati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tetzlaff</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.b2700</idno>
		<idno>Medline: 19622552</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VAXFj3K">BMJ</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page">2700</biblScope>
			<date type="published" when="2009-07-21">2009 Jul 21</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 Jul 21;339:b2700. [doi: 10.1136/ bmj.b2700] [Medline: 19622552]</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main" xml:id="_DEUf2qq">The Joanna Briggs Institute Reviewers&apos; Manual 2015: Methodology for JBI Scoping Reviews</title>
		<author>
			<persName><forename type="first">M</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Godfrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mcinerney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Soares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Khalil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Parker</surname></persName>
		</author>
		<idno type="DOI">10.7717/peerj.18108/table-3</idno>
		<imprint>
			<date type="published" when="2015">2015</date>
			<publisher>The Joanna Briggs Institute</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Peters M, Godfrey C, McInerney P, Soares C, Khalil H, Parker D. The Joanna Briggs Institute Reviewers&apos; Manual 2015: Methodology for JBI Scoping Reviews. The Joanna Briggs Institute; 2015.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_8hj48CP">RoB 2: a revised tool for assessing risk of bias in randomised trials</title>
		<author>
			<persName><forename type="first">Jac</forename><surname>Sterne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Savović</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Page</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.l4898</idno>
		<idno>Medline: 31462531</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9Xh5Sm5">BMJ</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page">4898</biblScope>
			<date type="published" when="2019-08-28">2019 Aug 28</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. [doi: 10.1136/bmj.l4898] [Medline: 31462531]</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_zqBzD4X">SMS reminders to improve the tuberculosis cure rate in developing countries (TB-SMS Cameroon): a protocol of a randomised control study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Bediang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Elia</surname></persName>
		</author>
		<idno type="DOI">10.1186/1745-6215-15-35</idno>
		<idno>Medline: 24460827</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NkN28ee">Trials</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">35</biblScope>
			<date type="published" when="2014-01-24">2014 Jan 24</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bediang G, Stoll B, Elia N, et al. SMS reminders to improve the tuberculosis cure rate in developing countries (TB-SMS Cameroon): a protocol of a randomised control study. Trials. 2014 Jan 24;15:35. [doi: 10.1186/1745-6215-15-35] [Medline: 24460827]</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_zeDKYCn">The effect of weekly text-message communication on treatment completion among patients with latent tuberculosis infection: study protocol for a randomised controlled trial (WelTel LTBI)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Van Der Kop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Memetovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patel</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2013-004362</idno>
		<idno>Medline: 24719431</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VN6u6Ym">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">4362</biblScope>
			<date type="published" when="2014-04-09">2014 Apr 9</date>
		</imprint>
	</monogr>
	<note type="raw_reference">van der Kop ML, Memetovic J, Patel A, et al. The effect of weekly text-message communication on treatment completion among patients with latent tuberculosis infection: study protocol for a randomised controlled trial (WelTel LTBI). BMJ Open. 2014 Apr 9;4(4):e004362. [doi: 10.1136/bmjopen-2013-004362] [Medline: 24719431]</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_ykse7eD">Impact of a daily SMS medication reminder system on tuberculosis treatment outcomes: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mohammed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Glennerster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Khan</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0162944</idno>
		<idno>Medline: 27802283</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RJM2WBv">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">162944</biblScope>
			<date type="published" when="2016-11-01">2016 Nov 1</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mohammed S, Glennerster R, Khan AJ. Impact of a daily SMS medication reminder system on tuberculosis treatment outcomes: a randomized controlled trial. PLoS One. 2016 Nov 1;11(11):e0162944. [doi: 10.1371/journal.pone.0162944] [Medline: 27802283]</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_7CQkWDZ">Text messaging to decrease tuberculosis treatment attrition in TB-HIV coinfection in Uganda</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Hermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Elbireer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tibakabikoba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Hoefman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Manabe</surname></persName>
		</author>
		<idno type="DOI">10.2147/ppa.s135540</idno>
		<idno>Medline: 28919720</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kUmeZXe">Patient Prefer Adherence</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1479" to="1487" />
			<date type="published" when="2017-08-31">2017 Aug 31</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hermans SM, Elbireer S, Tibakabikoba H, Hoefman BJ, Manabe YC. Text messaging to decrease tuberculosis treatment attrition in TB-HIV coinfection in Uganda. Patient Prefer Adherence. 2017 Aug 31;11:1479-1487. [doi: 10.2147/PPA. S135540] [Medline: 28919720]</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_6t3qWZe">The role of mobile SMS-reminders in improving drugs compliance in patients receiving anti-TB treatment from DOTS program</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Farooqi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ashraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zaman</surname></persName>
		</author>
		<ptr target="https://www.jpmi.org.pk/index.php/jpmi/article/view/2037/1854" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_FNgVMJp">Journal of Postgraduate Medical Institute</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="156" to="162" />
			<date type="published" when="2017-05-12">2017 May 12. 2023-11-10</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Farooqi RJ, Ashraf S, Zaman M. The role of mobile SMS-reminders in improving drugs compliance in patients receiving anti-TB treatment from DOTS program. Journal of Postgraduate Medical Institute. 2017 May 12;31(2):156-162. URL: https://www.jpmi.org.pk/index.php/jpmi/article/view/2037/1854 [Accessed 2023-11-10]</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_yZ7hPPr">SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial</title>
		<author>
			<persName><forename type="first">G</forename><surname>Bediang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Elia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Abena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Geissbuhler</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12889-018-5502-x</idno>
		<idno>Medline: 29720146</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VmetDSz">BMC Public Health</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">583</biblScope>
			<date type="published" when="2018-05-02">2018 May 2</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bediang G, Stoll B, Elia N, Abena JL, Geissbuhler A. SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial. BMC Public Health. 2018 May 2;18(1):583. [doi: 10.1186/s12889-018-5502-x] [Medline: 29720146]</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_dQNFkq2">ImPROving TB outcomes by modifying LIFE-style behaviours through a brief motivational intervention followed by short text messages (ProLife): study protocol for a randomised controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Moriarty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Louwagie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Mdege</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-019-3551-9</idno>
		<idno>Medline: 31349850</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7uWHrDc">Trials</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">457</biblScope>
			<date type="published" when="2019-07-26">2019 Jul 26</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moriarty AS, Louwagie GM, Mdege ND, et al. ImPROving TB outcomes by modifying LIFE-style behaviours through a brief motivational intervention followed by short text messages (ProLife): study protocol for a randomised controlled trial. Trials. 2019 Jul 26;20(1):457. [doi: 10.1186/s13063-019-3551-9] [Medline: 31349850]</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_2YBd55F">Protocol of a parallel group randomized control trial (RCT) for mobileassisted medication adherence support (Ma-MAS) intervention among tuberculosis patients</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Sahile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Perimal-Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Arbon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Maeder</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0261758</idno>
		<idno>Medline: 34972128</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dnaZpyV">PLoS One</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">261758</biblScope>
			<date type="published" when="2021-12-31">2021 Dec 31</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sahile Z, Perimal-Lewis L, Arbon P, Maeder AJ. Protocol of a parallel group randomized control trial (RCT) for mobile- assisted medication adherence support (Ma-MAS) intervention among tuberculosis patients. PLoS One. 2021 Dec 31;16(12):e0261758. [doi: 10.1371/journal.pone.0261758] [Medline: 34972128]</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_9uyYBHg">Bracelet-and self-directed observational therapy for control of tuberculosis: study protocol for a cluster randomized controlled trial</title>
		<author>
			<persName><forename type="first">R</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hu</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-017-1996-2</idno>
		<idno>Medline: 28673323</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qZmRwve">Trials</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">286</biblScope>
			<date type="published" when="2017-07-04">2017 Jul 4</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huang R, Ren G, Hu J. Bracelet-and self-directed observational therapy for control of tuberculosis: study protocol for a cluster randomized controlled trial. Trials. 2017 Jul 4;18(1):286. [doi: 10.1186/s13063-017-1996-2] [Medline: 28673323]</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_AbPtjrn">Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Browne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Umlauf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Tucker</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.1002891</idno>
		<idno>Medline: 31584944</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GBW8sTq">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">1002891</biblScope>
			<date type="published" when="2019-10-04">2019 Oct 4</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Browne SH, Umlauf A, Tucker AJ, et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: a randomized controlled trial. PLoS Med. 2019 Oct 4;16(10):e1002891. [doi: 10.1371/journal.pmed.1002891] [Medline: 31584944]</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_WA86Mrm">Use of smartphone-based video directly observed therapy (vDOT) in tuberculosis care: single-arm, prospective feasibility study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Holzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Atre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sahasrabudhe</surname></persName>
		</author>
		<idno type="DOI">10.2196/13411</idno>
		<idno>Medline: 31456581</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fA8WqSG">JMIR Form Res</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">13411</biblScope>
			<date type="published" when="2019-08-27">2019 Aug 27</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Holzman SB, Atre S, Sahasrabudhe T, et al. Use of smartphone-based video directly observed therapy (vDOT) in tuberculosis care: single-arm, prospective feasibility study. JMIR Form Res. 2019 Aug 27;3(3):e13411. [doi: 10.2196/ 13411] [Medline: 31456581]</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_t6Xf5MM">Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Story</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Aldridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(18)32993-3</idno>
		<idno>Medline: 30799062</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Na3nN7w">Lancet</title>
		<imprint>
			<biblScope unit="volume">393</biblScope>
			<biblScope unit="issue">10177</biblScope>
			<biblScope unit="page" from="1216" to="1224" />
			<date type="published" when="2019-03-23">2019 Mar 23</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Story A, Aldridge RW, Smith CM, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet. 2019 Mar 23;393(10177):1216-1224. [doi: 10.1016/S0140-6736(18)32993-3] [Medline: 30799062]</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_fqBzGBJ">People-centred care versus clinic-based DOT for continuation phase TB treatment in Armenia: a cluster randomized trial</title>
		<author>
			<persName><forename type="first">V</forename><surname>Khachadourian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Truzyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Harutyunyan</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12890-020-1141-y</idno>
		<idno>Medline: 32334553</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6QgEAXJ">BMC Pulm Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">105</biblScope>
			<date type="published" when="2020-04-25">2020 Apr 25</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Khachadourian V, Truzyan N, Harutyunyan A, et al. People-centred care versus clinic-based DOT for continuation phase TB treatment in Armenia: a cluster randomized trial. BMC Pulm Med. 2020 Apr 25;20(1):105. [doi: 10.1186/ s12890-020-1141-y] [Medline: 32334553]</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_EsSXe74">Study protocol and implementation details for a pragmatic, steppedwedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion</title>
		<author>
			<persName><forename type="first">R</forename><surname>Crowder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kityamuwesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kiwanuka</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2020-039895</idno>
		<idno>Medline: 33247012</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dc239cW">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">39895</biblScope>
			<date type="published" when="2020-11-27">2020 Nov 27</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Crowder R, Kityamuwesi A, Kiwanuka N, et al. Study protocol and implementation details for a pragmatic, stepped- wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion. BMJ Open. 2020 Nov 27;10(11):e039895. [doi: 10.1136/bmjopen-2020-039895] [Medline: 33247012]</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_rY7ZHGq">Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ravenscroft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kettle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Persian</surname></persName>
		</author>
		<idno type="DOI">10.1183/13993003.00493-2020</idno>
		<idno>Medline: 32381495</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pHZrCCU">Eur Respir J</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">2000493</biblScope>
			<date type="published" when="2020-08-06">2020 Aug 6</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ravenscroft L, Kettle S, Persian R, et al. Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova. Eur Respir J. 2020 Aug 6;56(2):2000493. [doi: 10.1183/13993003.00493-2020] [Medline: 32381495]</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_QAGBZCF">Short and long-term outcomes of video observed treatment in tuberculosis patients, the Republic of Moldova</title>
		<author>
			<persName><forename type="first">S</forename><surname>Doltu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ciobanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sereda</surname></persName>
		</author>
		<idno type="DOI">10.3855/jidc.14601</idno>
		<idno>Medline: 34609956</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CxCnnXQ">J Infect Dev Ctries</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">9.1</biblScope>
			<biblScope unit="page" from="17S" to="24S" />
			<date type="published" when="2021-09-29">2021 Sep 29</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Doltu S, Ciobanu A, Sereda Y, et al. Short and long-term outcomes of video observed treatment in tuberculosis patients, the Republic of Moldova. J Infect Dev Ctries. 2021 Sep 29;15(9.1):17S-24S. [doi: 10.3855/jidc.14601] [Medline: 34609956]</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_gNX3PCY">In-person vs electronic directly observed therapy for tuberculosis treatment adherence: a randomized noninferiority trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Burzynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mangan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Lam</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamanetworkopen.2021.44210</idno>
		<idno>Medline: 35050357</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_d8hYEBr">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">2144210</biblScope>
			<date type="published" when="2022-01-04">2022 Jan 4</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Burzynski J, Mangan JM, Lam CK, et al. In-person vs electronic directly observed therapy for tuberculosis treatment adherence: a randomized noninferiority trial. JAMA Netw Open. 2022 Jan 4;5(1):e2144210. [doi: 10.1001/ jamanetworkopen.2021.44210] [Medline: 35050357]</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_hFUhjC3">Evaluation of a medication monitor-based treatment strategy for drug-sensitive tuberculosis patients in China: study protocol for a cluster randomised controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-018-2650-3</idno>
		<idno>Medline: 30045757</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pQN9kQF">Trials</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">398</biblScope>
			<date type="published" when="2018-07-25">2018 Jul 25</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lewis JJ, Liu X, Zhang Z, et al. Evaluation of a medication monitor-based treatment strategy for drug-sensitive tuberculosis patients in China: study protocol for a cluster randomised controlled trial. Trials. 2018 Jul 25;19(1):398. [doi: 10.1186/s13063-018-2650-3] [Medline: 30045757]</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_DFy2wNC">Electronic pillbox-enabled selfadministered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial</title>
		<author>
			<persName><forename type="first">T</forename><surname>Manyazewal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Woldeamanuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Holland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fekadu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Blumberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Marconi</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-020-04324-z</idno>
		<idno>Medline: 32370774</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_B94bfMz">Trials</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">383</biblScope>
			<date type="published" when="2020-05-05">2020 May 5</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Manyazewal T, Woldeamanuel Y, Holland DP, Fekadu A, Blumberg HM, Marconi VC. Electronic pillbox-enabled self- administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial. Trials. 2020 May 5;21(1):383. [doi: 10.1186/s13063-020-04324-z] [Medline: 32370774]</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_qmsaKWF">Ensuring tuberculosis treatment adherence with a mobile-based CARE-call system in Thailand: a pilot study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ratchakit-Nedsuwan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nedsuwan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sawadna</surname></persName>
		</author>
		<idno type="DOI">10.1080/23744235.2019.1688862</idno>
		<idno>Medline: 31710250</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ty3DsXb">Infect Dis (Lond)</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="121" to="129" />
			<date type="published" when="2020-02">2020 Feb</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ratchakit-Nedsuwan R, Nedsuwan S, Sawadna V, et al. Ensuring tuberculosis treatment adherence with a mobile-based CARE-call system in Thailand: a pilot study. Infect Dis (Lond). 2020 Feb;52(2):121-129. [doi: 10.1080/23744235.2019. 1688862] [Medline: 31710250]</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_ys2xBPf">Evaluation of adherence monitoring system using evriMED with a differentiated response compared to standard of care among drug-sensitive TB patients in three provinces in South Africa: a protocol for a cluster randomised control trial</title>
		<author>
			<persName><forename type="first">N</forename><surname>Maraba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Orrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Chetty-Makkan</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-021-05337-y</idno>
		<idno>Medline: 34108036</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Zq9ZKBw">Trials</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">389</biblScope>
			<date type="published" when="2021-06-09">2021 Jun 9</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Maraba N, Orrell C, Chetty-Makkan CM, et al. Evaluation of adherence monitoring system using evriMED with a differentiated response compared to standard of care among drug-sensitive TB patients in three provinces in South Africa: a protocol for a cluster randomised control trial. Trials. 2021 Jun 9;22(1):389. [doi: 10.1186/s13063-021-05337- y] [Medline: 34108036]</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_3CHQAnX">Evaluation of implementation and effectiveness of digital adherence technology with differentiated care to support tuberculosis treatment adherence and improve treatment outcomes in Ethiopia: a study protocol for a cluster randomised trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Tadesse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Mohammed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Foster</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12879-021-06833-x</idno>
		<idno>Medline: 34758737</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MBhquX7">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">1149</biblScope>
			<date type="published" when="2021-11-10">2021 Nov 10</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tadesse AW, Mohammed Z, Foster N, et al. Evaluation of implementation and effectiveness of digital adherence technology with differentiated care to support tuberculosis treatment adherence and improve treatment outcomes in Ethiopia: a study protocol for a cluster randomised trial. BMC Infect Dis. 2021 Nov 10;21(1):1149. [doi: 10.1186/ s12879-021-06833-x] [Medline: 34758737]</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_vUNxG2h">A randomised controlled trial to evaluate a medication monitoring system for TB treatment</title>
		<author>
			<persName><forename type="first">J</forename><surname>Acosta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Flores</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alarcón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grande-Ortiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Moreno-Exebio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">M</forename><surname>Puyen</surname></persName>
		</author>
		<idno type="DOI">10.5588/ijtld.21.0373</idno>
		<idno>Medline: 34969428</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vfbEtvp">Int J Tuberc Lung Dis</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="44" to="49" />
			<date type="published" when="2022-01-01">2022 Jan 1</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Acosta J, Flores P, Alarcón M, Grande-Ortiz M, Moreno-Exebio L, Puyen ZM. A randomised controlled trial to evaluate a medication monitoring system for TB treatment. Int J Tuberc Lung Dis. 2022 Jan 1;26(1):44-49. [doi: 10.5588/ijtld.21. 0373] [Medline: 34969428]</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_qD4fcfp">Effectiveness of health education module delivered through WhatsApp to enhance treatment adherence and successful outcome of tuberculosis in Seremban District, Negeri Sembilan, Malaysia</title>
		<author>
			<persName><forename type="first">I</forename><surname>Noorhaslinda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Juni</surname></persName>
		</author>
		<idno type="DOI">10.32827/ijphcs.6.4.145</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vNRVd5u">International Journal of Public Health and Clinical Sciences</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="145" to="159" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">NoorHaslinda I, Juni MH. Effectiveness of health education module delivered through WhatsApp to enhance treatment adherence and successful outcome of tuberculosis in Seremban District, Negeri Sembilan, Malaysia. International Journal of Public Health and Clinical Sciences. 2019;6(4):145-159. [doi: 10.32827/ijphcs.6.4.145]</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_pXRHhYY">Protocol for a randomised controlled trial to evaluate the effectiveness of improving tuberculosis patients&apos; treatment adherence via electronic monitors and an app versus usual care in Tibet</title>
		<author>
			<persName><forename type="first">X</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pasang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-019-3364-x</idno>
		<idno>Medline: 31097023</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EMszXme">Trials</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">273</biblScope>
			<date type="published" when="2019-05-16">2019 May 16</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wei X, Hicks JP, Pasang P, et al. Protocol for a randomised controlled trial to evaluate the effectiveness of improving tuberculosis patients&apos; treatment adherence via electronic monitors and an app versus usual care in Tibet. Trials. 2019 May 16;20(1):273. [doi: 10.1186/s13063-019-3364-x] [Medline: 31097023]</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_sA2Ej4T">Impact of a mobile phone-based interactive voice response software on tuberculosis treatment outcomes in Uganda (CFL-TB): a protocol for a randomized controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Byonanebye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mackline</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sekaggya-Wiltshire</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-021-05352-z</idno>
		<idno>Medline: 34120649</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yt8K6dD">Trials</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">391</biblScope>
			<date type="published" when="2021-06-13">2021 Jun 13</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Byonanebye DM, Mackline H, Sekaggya-Wiltshire C, et al. Impact of a mobile phone-based interactive voice response software on tuberculosis treatment outcomes in Uganda (CFL-TB): a protocol for a randomized controlled trial. Trials. 2021 Jun 13;22(1):391. [doi: 10.1186/s13063-021-05352-z] [Medline: 34120649]</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_Csnu6g2">The effect of a mhealth intervention on anti-tuberculosis medication adherence in Delhi, India: a quasi-experimental study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Santra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Basu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Khanna</surname></persName>
		</author>
		<idno type="DOI">10.4103/ijph.IJPH_879_20</idno>
		<idno>Medline: 33753687</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8XGGqgh">Indian J Public Health</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="34" to="38" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Santra S, Garg S, Basu S, Sharma N, Singh MM, Khanna A. The effect of a mhealth intervention on anti-tuberculosis medication adherence in Delhi, India: a quasi-experimental study. Indian J Public Health. 2021;65(1):34-38. [doi: 10. 4103/ijph.IJPH_879_20] [Medline: 33753687]</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_MHyPRwZ">Medication adherence: a review of the literature and implications for clinical practice</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Julius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Novitsky</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Dubin</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.pra.0000344917.43780.77</idno>
		<idno>Medline: 19182563</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uP2u7zn">J Psychiatr Pract</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="34" to="44" />
			<date type="published" when="2009-01">2009 Jan</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract. 2009 Jan;15(1):34-44. [doi: 10.1097/01.pra.0000344917.43780.77] [Medline: 19182563]</note>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<idno type="DOI">10.31219/osf.io/n2w5c</idno>
		<ptr target="https://acarepro.abbott.com/adherence-behavioral-science/" />
		<title level="m" xml:id="_nwg6J8G">Adherence &amp; behavioral science</title>
		<imprint>
			<date type="published" when="2023-11-10">2023-11-10</date>
		</imprint>
	</monogr>
	<note>Acare HCP Global</note>
	<note type="raw_reference">Adherence &amp; behavioral science. Acare HCP Global. URL: https://acarepro.abbott.com/adherence-behavioral-science/ [Accessed 2023-11-10]</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_SebPwzn">Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Karnon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Eliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hiller</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0050155</idno>
		<idno>Medline: 23226243</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FzGHrxJ">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">50155</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wade VA, Karnon J, Eliott JA, Hiller JE. Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. PLoS One. 2012;7(11):e50155. [doi: 10.1371/journal.pone.0050155] [Medline: 23226243]</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_vRKdH8p">Treatment adherence and illness self-management: introduction to the special issue</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Howren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Gonzalez</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10865-016-9804-0</idno>
		<idno>Medline: 27766482</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MB4h3Zy">J Behav Med</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="931" to="934" />
			<date type="published" when="2016-12">2016 Dec</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Howren MB, Gonzalez JS. Treatment adherence and illness self-management: introduction to the special issue. J Behav Med. 2016 Dec;39(6):931-934. [doi: 10.1007/s10865-016-9804-0] [Medline: 27766482]</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_wWQy29d">Determinants of self-management behaviors among pulmonary tuberculosis patients: a path analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1186/s40249-021-00888-3</idno>
		<idno>Medline: 34330337</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W6WeKmD">Infect Dis Poverty</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">103</biblScope>
			<date type="published" when="2021-07-30">2021 Jul 30</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li J, Pu J, Liu J, et al. Determinants of self-management behaviors among pulmonary tuberculosis patients: a path analysis. Infect Dis Poverty. 2021 Jul 30;10(1):103. [doi: 10.1186/s40249-021-00888-3] [Medline: 34330337]</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_3XmTMkv">The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials</title>
		<author>
			<persName><forename type="first">A</forename><surname>Vernon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Savic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dodd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nahid</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.1002884</idno>
		<idno>Medline: 31821323</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5HhHVNP">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">1002884</biblScope>
			<date type="published" when="2019-12-10">2019 Dec 10</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vernon A, Fielding K, Savic R, Dodd L, Nahid P. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials. PLoS Med. 2019 Dec 10;16(12):e1002884. [doi: 10.1371/journal. pmed.1002884] [Medline: 31821323]</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
